latest news releases from the newsroom
GLOBALFOUNDRIES Americas, Inc.
Chartered, Tezzaron Team Up to Deliver Ultra High-Speed Memory Solution
MILPITAS, Calif., June 12, 2007 (PRIME NEWSWIRE) -- Chartered Semiconductor Manufacturing (Nasdaq:CHRT) and (SGX-ST:Chartered), one of the world's top dedicated foundries, and Tezzaron Semiconductor, a specialist in high-speed memory solutions and three-dimensional (3D) wafer stacking processes, today announced that Chartered is beginning to ramp production of Tezzaron's unique ultra high-speed memory chips. In addition, the two companies are working on the manufacture of Tezzaron's groundbreaking 3D devices, and hope to see them become the first 3D ICs to be manufactured in volume.
Worldwide Energy Corp.
Worldwide Energy Corp. to Seek a Listing on the American Stock Exchange
SEATTLE, June 12, 2007 (PRIME NEWSWIRE) -- Worldwide Energy Corp. (Pink Sheets:WWEG) is pleased to announce that the Company intends to make an application for listing of its common stock on the American Stock Exchange. The Company is engaged in the acquisition, exploration, and development of properties for production of crude oil and natural gas. Worldwide Energy Corp. plans to acquire additional leases to gain the capital needed to up list to the AMEX or a higher exchange such as the NASDAQ.
News of China, Inc.
News of China, Inc. Prepares for Opening of New Office
MONTREAL, June 12, 2007 (PRIME NEWSWIRE) -- News of China Inc., (OTCBB:NWCH) an online financial media for researching China based publicly traded companies, announced today the board of directors has unanimously agreed to open a new branch office in Beijing, China, the firm's first overseas office.
FDA Grants Ceragenix's Request for Designation
DENVER, Jun 12, 2007 -- Ceragenix Pharmaceuticals, Inc. (CGXP), a biopharmaceutical company focused on infectious disease and dermatology, today announced that the FDA's Office of Combination Products, in response to a formal request, has determined that the primary mode of action for an antimicrobial wound dressing that is currently being developed by the Company is that of a device and it has been assigned to the FDA's Center for Devices and Radiologic Health (CDRH) for lead review. The device will be reviewed through the pre-market approval process to confirm reasonable assurance of safety and effectiveness.